ARTELO BIOSCIENCES, INC. (ARTL) Stock Price, Financials & Summary

Price chart

Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30

Key dataOct 30, 2026

Open$2.27

From 52W high−97.63%

Volume3248.00

Market cap$1.23M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 30, 2026

Open

$2.27

From 52W high

−97.63%

Volume

3248.00

Market cap

$1.23M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

P/E (TTM)

—

RSI (14)

32.1

MomentumView details →

1D Return

−2.65%

YTD Return

−78.14%

SummaryUpdated Jun 1, 2026

Artelo Biosciences, Inc. (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Solana Beach, California. Originally incorporated as Reactive Medical, Inc., the company rebranded to Artelo Biosciences in April 2017 and went public in June 2019. Artelo specializes in developing therapeutic treatments that target the endocannabinoid system, a complex cell-signaling system in the human body that plays a role in regulating various physiological processes including appetite, pain sensation, mood, and immune function.

Ask drillr about ARTELO BIOSCIENCES, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−253.57%

ROA (TTM)

−196.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−89.91%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−15.68%

MomentumView details →

1D Return

−2.65%

YTD Return

−78.14%

1Y Return

−91.40%

RSI (14)

32.1

vs 50D SMA

−45.13%

vs 200D SMA

−87.49%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.00x

Quick Ratio

3.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.89

EPS Surprise

−23.61%

Beats (12Q)

3/12

Next Q EPS Est

−$7.83

Avg Surprise (4Q)

−244.61%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−12.67M

Op. CF (TTM)

−12.63M

Next earningsNov 17, 2026 →

Latest newsMore news →

ARTELO BIOSCIENCES, INC. announced that it will present data on ART27.13’s potential to treat chemotherapy-induced neuropathic pain at the ARTELO BIOSCIENCES, INC..1d ago

ARTELO BIOSCIENCES, INC. plans to showcase its FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain.4d ago

Similar companies

Protagenic Therapeutics, Inc.PTIX Avenue Therapeutics, Inc.ATXI Abpro CorporationABP Iterum Therapeutics plcITRM Liminatus Pharma, Inc. WarrantsLIMNW GeoVax Labs, Inc.GOVX Find similar companies →

Latest newsMore news →

ARTELO BIOSCIENCES, INC. announced that it will present data on ART27.13’s potential to treat chemotherapy-induced neuropathic pain at the ARTELO BIOSCIENCES, INC..1d ago ARTELO BIOSCIENCES, INC. plans to showcase its FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain.4d ago